BIOMAT Database Logo BIOMAT Database Logo

Evidence for endogenous opioid control of vasopressin release in man. 1980

S L Lightman, and M L Forsling

The role of endogenous opioids in the control of vasopressin secretion was studied using the pure opiate antagonist naloxone. Naloxone both reduced resting levels of vasopressin and inhibited the rise in vasopressin induced by an orthostatic stimulus. These results suggest that endogenous opioids are important as a tonic stimulus to vasopressin release in man.

UI MeSH Term Description Entries
D008297 Male Males
D009270 Naloxone A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. MRZ 2593-Br,MRZ-2593,Nalone,Naloxon Curamed,Naloxon-Ratiopharm,Naloxone Abello,Naloxone Hydrobromide,Naloxone Hydrochloride,Naloxone Hydrochloride Dihydride,Naloxone Hydrochloride, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Naloxone, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Narcan,Narcanti,Abello, Naloxone,Curamed, Naloxon,Dihydride, Naloxone Hydrochloride,Hydrobromide, Naloxone,Hydrochloride Dihydride, Naloxone,Hydrochloride, Naloxone,MRZ 2593,MRZ 2593 Br,MRZ 2593Br,MRZ2593,Naloxon Ratiopharm
D004723 Endorphins One of the three major groups of endogenous opioid peptides. They are large peptides derived from the PRO-OPIOMELANOCORTIN precursor. The known members of this group are alpha-, beta-, and gamma-endorphin. The term endorphin is also sometimes used to refer to all opioid peptides, but the narrower sense is used here; OPIOID PEPTIDES is used for the broader group. Endorphin
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001127 Arginine Vasopressin The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE. Argipressin,Vasopressin, Arginine,Arg-Vasopressin,Argipressin Tannate,Arg Vasopressin

Related Publications

S L Lightman, and M L Forsling
Evidence for endogenous dopaminergic control of GH release in man.
September 1981, The Tohoku journal of experimental medicine,
S L Lightman, and M L Forsling
Opioid control of vasopressin and oxytocin release.
April 1993, Regulatory peptides,
S L Lightman, and M L Forsling
Endogenous opioid mediation of somatostatin inhibition of arginine vasopressin release evoked by insulin-induced hypoglycemia in man.
January 1991, Journal of neural transmission. General section,
S L Lightman, and M L Forsling
Endogenous vasopressin affects postural control of blood pressure in man.
December 1987, Clinical science (London, England : 1979),
S L Lightman, and M L Forsling
Endogenous vasopressin and postural control of blood pressure in man.
May 1988, Clinical science (London, England : 1979),
S L Lightman, and M L Forsling
Evidence for endogenous opioid release in the amygdala during positive emotion.
January 2009, NeuroImage,
S L Lightman, and M L Forsling
Endogenous opioids inhibit oxytocin release during nicotine-stimulated secretion of vasopressin in man.
May 1988, Clinical endocrinology,
S L Lightman, and M L Forsling
Vasopressin test for corticotrophin release in man.
January 1967, Medicina et pharmacologia experimentalis. International journal of experimental medicine,
S L Lightman, and M L Forsling
Naloxone antagonism of conditioned hyperthermia: an evidence for release of endogenous opioid.
May 1976, Life sciences,
S L Lightman, and M L Forsling
Effects of naloxone on vasopressin secretion in conscious rats: evidence for inhibitory role of endogenous opioid peptides in vasopressin secretion.
August 1989, Endocrinology,
Copied contents to your clipboard!